🇮🇳-Healthcare Allocation in Budget Up ~6.6% to ₹1.06 Trillion
🇮🇳-Healthcare Allocation in Budget Up ~6.6% to ₹1.06 Trillion
The Union Budget 2026-27 increased overall healthcare allocation to ₹1.06 trillion, a nearly 10% rise over revised estimates, with a renewed emphasis on tackling non-communicable diseases like diabetes and cancer through expanded public health spending and targeted schemes.
Big Pharma Cost Relief Coming by March — Drug Prices Likely to Drop
The Indian government plans to remove customs duties on 17 high-cost medicines, including expensive cancer drugs like ribociclib and abemaciclib. This move is expected to significantly lower prices by the end of March, making critical treatments more affordable — though retailers are seeking clarity on implementation and inventory pricing. (The Times of India)
Construction of Ayush Hospitals Begins in 7 Districts
The government has announced the start of Ayush hospital construction in seven districts to expand traditional healthcare services under Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homeopathy. This reflects a broader push to integrate holistic and preventive careinto the healthcare system.
Union Budget Rolls Out ₹10,000 Cr ‘Biopharma Shakti’ Plan
In Budget 2026-27, the government launched Biopharma Shakti, a ₹10,000 crore initiative aimed at strengthening India’s biologics and biosimilars ecosystem — boosting domestic manufacturing, R&D and global competitiveness. Experts say this is a strategic pivot toward innovation-led growth in life sciences.
India’s OTC Pharmaceutical Market on Growth Track
A recent EY-Parthenon report finds India’s over-the-counter (OTC) drugs market is projected to nearly double to ₹98,000 crore by 2030, growing at ~13% CAGR — a sign of rising consumer self-care demand and shifting pharmaceutical consumption patterns.
(EY)
📌 Daily Pulse Insight
✔ Affordability boost:Duty removal on key medicines can make life-saving treatments cheaper soon.
✔ Holistic care expansion:Ayush hospitals underscore preventive and traditional care integration.
✔ Innovation focus:Biopharma Shakti signals India’s intent to lead in biologics and biosimilars.
✔ Stronger budget backing:Increased healthcare allocation shows policy commitment to health system resilience.
✔ Consumer health growth: OTC segment is emerging as a significant market driver.
✨ Follow Daily Pulse for crisp, verified healthcare & pharma updates — delivered daily.
Leave a Comment